NCT05227768 - Safety and Pharmacokinetics Study of Single Ascending Doses of VV116 in Healthy Volunteers | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 11, 2021

Primary Completion Date

January 13, 2022

Study Completion Date

January 13, 2022

Conditions

Healthy Subjects

Interventions

DRUG

VV116 25mg Group

4 subjects will receive VV116 25mg,orally; 2 subjects will receive placebo,orally.

DRUG

VV116 200mg Group

6 subjects will receive VV116 200mg,orally; 2 subjects will receive placebo,orally.

DRUG

VV116 400mg Group

6 subjects will receive VV116 400mg,orally; 2 subjects will receive placebo,orally.

DRUG

VV116 800mg Group

6 subjects will receive VV116 800mg,orally; 2 subjects will receive placebo,orally.

DRUG

VV116 1200mg Group

6 subjects will receive VV116 1200mg,orally; 2 subjects will receive placebo,orally.

Trial Locations (1)

Shanghai Xuhui Central Hospital, Shanghai

All Listed Sponsors

lead

Vigonvita Life Sciences

INDUSTRY